Epidiolex (Cannabidiol (Cbd)) Patent Expiration, LOE Window & CMS Spending
Epidiolex (Cannabidiol (Cbd)) by Jazz Pharmaceuticals: FDA Orange Book core substance LOE 2039-04-26 (last listed 2042-09-24), 0 AB generics, $726.6M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Jazz Pharmaceuticals |
| FDA Application & Pathway | N210365 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2039-04-26 |
| Last Listed Patent or Exclusivity Date | 2042-09-24 |
| Orange Book Patents (*PED Extensions) | 33 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $726.6M |
| 2024 Medicare Part D Spend | $207.4M |
| 2024 Medicaid Spend | $519.2M |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 19.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Jazz Pharmaceuticals across sibling Meru public-data platforms.